DeCure for Type II complement component 8 deficiency
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for type II complement component 8 deficiency — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleType II complement component 8 deficiency maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for type ii complement component 8 deficiency is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
No abstract in this set reports a clinical trial or treatment for type II complement component 8 deficiency. The abstracts are reviews or general discussions. One 1990 review states that for autoimmune immune complex disease in complement deficiency, safe and effective methods to treat asymptomatic patients before they develop disease are not yet available. A 2012 review notes that deficiency of complement components can lead to life-threatening conditions and that complement-targeted therapies exist, but gives no specific results for C8 deficiency. A 2020 review mentions that complement deficiency diseases are often not recognised despite available diagnostic tools, and that targeted drugs are now widespread, but again provides no data on C8 deficiency. The remaining abstracts discuss the complement system in general or terminal complement complex epitopes, without addressing treatment of C8 deficiency.
No survival rates, response rates, or sample sizes for any drug in type II complement component 8 deficiency appear in these abstracts. There is no evidence of efficacy for any specific treatment. The abstracts do not contradict each other because none report original clinical data on this condition.
What is missing: any clinical trial testing a drug specifically for type II complement component 8 deficiency, any patient outcome data, any evidence that complement-targeted therapies have been tried in this exact deficiency, and any discussion of patient stratification or trial design for this rare disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1967 · 20 citations
Inborn Errors of the Complement System of Man
AbstractTWO inborn errors of the complement system of man have been well documented: hereditary deficiency of the serum inhibitor of the activated first component of complement (C′1a) and hereditary deficiency of the second component of complement (C′2). To appreciate both the nature of the inborn errors and their possible consequences, it is necessary to review very briefly certain basic aspects of the complement system.The sequence in which the components of complement act in immune hemolysis is depicted in Figure 1; this scheme is based on studies by many investigators using both guinea pig and human complement (reviewed by Rapp and . . .
International Reviews of Immunology · 2020 · 16 citations
Complement system network in cell physiology and in human diseases
AbstractThe complement system is a multi-functional system representing the first line host defense against pathogens in innate immune response, through three different pathways. Impairment of its function, consisting in deficiency or excessive deregulated activation, may lead to severe systemic infections or autoimmune disorders. These diseases may be inherited or acquired. Despite many diagnostic tools are currently available, ranging from traditional, such as hemolytic or ELISA based assays, to innovative ones, like next generation sequencing techniques, these diseases are often not recognized. As for therapeutic aspects, strategies based on the use of targeted drugs are now widespread. The aim of this review is to present an updated overview of complement system pathophysiology, clinical implications of its dysfunction and to summarize diagnostic and therapeutic approaches.
Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · 1990 · 13 citations
Complement Deficiency and the Pathogenesis of Autoimmune Immune Complex Disease
AbstractIn the case of the autoimmune immune complex disease it is, however, apparently the effector side that is at fault and this does suggest that it may be advisable to treat asymptomatic patients with deficiencies of the early components of the complement pathway before they develop disease and perhaps to try to avoid prolonged complement depression occurring in disease although it must be confessed that safe and effective methods of so doing are not yet available
Activation-Dependent Epitopes in the Terminal Complement Pathway
AbstractAssembly of the terminal complement complex (TCC) during complement activation is associated with considerable antigenic changes in the individual C5, C6, C7, C8 and C9 components. Numerous neoepitopes specific for the TCC are exposed. Similarly, native-restricted epitopes specific for the nonactivated components are concealed in the TCC. The present paper reviews these antigenic changes with special reference to available monoclonal antibodies and their utilization in assays to detect and quantify the TCC. Application of such assays in clinical medicine is discussed. Finally, a recommended terminology for the terminal complement pathway is put forward.
Modern complement analysis: indications, methods and outlook<sup>1),2)</sup>
AbstractAbstract Complement is one of the key systems of innate immunity and homeostasis. Its excessive activation and also a deficiency of complement components or regulators can lead to life-threatening conditions. This review aims to provide the basic knowledge that clinicians need in order to understand complement-related diseases. Moreover, it shows possible indications and interpretations of a complement analysis and explains the rationale behind complement-targeted therapies.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
